|
- About UCB | UCB
At UCB, we believe that everyone deserves to live the best life that they can That’s why – as a global biopharmaceutical leader - we’re focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions
- Inspired by Patients. Driven by Science.
UCB a global biopharmaceutical leader focuses on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions
- Investors - UCB
UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease This ambition fuels our purpose: creating value in the lives of the people we serve, now and into the future
- Carrières chez UCB | Emplois UCB
Repoussons ensemble les limites et tirons le meilleur parti de vos talents Trouvez des offres d'emploi dans des domaines tels que la fince, les affaires médicales et le développement clinique, les ventes et le marketing, etc
- Press releases - UCB
UCB presents expansive data set at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference highlighting commitment to advancing gMG treatment outcomes and experiences
- Medicines - UCB
For patients: if you wish to report an adverse event related to one of our products, please contact your healthcare provider In addition you can contact us using your local safety officer, via UCBCares or via this webportal For healthcare professionals: if you wish to report an adverse event related to one of our products, please follow the current regulatory procedure in force in your
- Careers at UCB | UCB jobs
Let's push the boundaries together and make the most of your talents Find available jobs in fields like Finance, Medical Clinical, Sales Marketing and more
- On Growth Path for a Decade plus: Strong Launch Execution driving . . .
UCB Full-Year Report 2024, Brussels (Belgium), 27 February 2025 – 7:00 (CET) – regulated information Jean-Christophe Tellier, CEO UCB says: “Our 2024 performance demonstrates that we are progressing on our path of growth for a decade+ and underlines our unwavering commitment to ensuring people with severe diseases can live the best life that they can, as free as possible from
|
|
|